Source: Eur Respir J 2016; 48: 1307-1319
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Susan J. Wilson, Jonathan A. Ward, Ana R. Sousa, Julie Corfield, Aruna T. Bansal, Bertrand De Meulder, Diane Lefaudeux,Charles Auffray, Matthew J. Loza, Frederic Baribaud, Neil Fitch, Peter J. Sterk, Kian Fan Chung, David Gibeon, Kai Sun, Yi-ke Guo, Ian Adcock, Ratko Djukanovic, Barbro Dahlen, Pascal Chanez, Dominick Shaw, Norbert Krug, Jens Hohlfeld, Thomas Sandström and Peter H. Howarth on behalf of the U-BIOPRED Study Group. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. Eur Respir J 2016; 48: 1307-1319

Member's Comments

No comment yet.

Related content which might interest you: Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients Source: International Congress 2016 – From microimaging to functional evaluation of the lung Year: 2016 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Severe asthma: from inflammatory phenotype to treatment Source: International Congress 2017 – Chinese Programme 2017 Year: 2017 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Source: Eur Respir J 2003; 22: 470-477 Year: 2003 The pathology and immunology of difficult childhood asthma Source: Annual Congress 2005 - Difficult asthma in children Year: 2005 Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma Source: International Congress 2016 – Airway biomarkers Year: 2016 Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme Source: Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019 Year: 2020 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Current control, airway inflammation, and subsequent exacerbation in patients with asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 On relationship between local and systemic chronic inflammation and between level of hypoxia and bronchial obstruction in COPD pts Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Treatment of severe childhood asthma: what’s the evidence? Source: Annual Congress 2005 - Difficult asthma in children Year: 2005 Alamandine reduces eosinophilic inflammation in an experimental model of asthma Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Two novel, severe asthma phenotypes identified during childhood using a clustering approach Source: Eur Respir J 2012; 40: 55-60 Year: 2012 Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006 Patients with persistent asthma may have poor disease control despite normal lung function: baseline data from a pan-European real-life study Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Lung development and the role of asthma and allergy Source: Eur Respir Mon 2012; 56: 82-96 Year: 2012